1 | combined | 29,205 |
2 | coadministered | 368 |
3 | co-administered | 355 |
4 | co-formulated | 23 |
5 | trfh | 10 |
6 | lv-peg | 8 |
7 | refitted | 8 |
8 | hyperpulse | 7 |
9 | sv-peg | 7 |
10 | capsule-based | 5 |
11 | probiotical | 5 |
12 | tocct | 5 |
13 | co-segregating | 4 |
14 | diet-based | 4 |
15 | pa-pals | 4 |
16 | tarpana | 4 |
17 | thiosemicarbazides | 4 |
18 | ufox | 4 |
19 | dp-δ24/28cpe | 3 |
20 | eb4k | 3 |
21 | empathizing | 3 |
22 | ergotism | 3 |
23 | neoureterostomy | 3 |
24 | predosed | 3 |
25 | autorefraktokeratometer | 2 |
26 | biflagellate | 2 |
27 | chromoscopic | 2 |
28 | formylated | 2 |
29 | imidazolyl-3-position | 2 |
30 | information-delivery | 2 |
31 | medoxomil-induced | 2 |
32 | not-cured | 2 |
33 | puerpera | 2 |
34 | radiotherapy-based | 2 |
35 | 1,3-azadienes | 1 |
36 | 2-thienylbbr2·pph3 | 1 |
37 | agpf6 | 1 |
38 | assistant/physical | 1 |
39 | associeted | 1 |
40 | azathioprine/6-mercaptopurine | 1 |
41 | bpi- | 1 |
42 | cmc-protocol | 1 |
43 | cone-erg | 1 |
44 | crimpled | 1 |
45 | cross-pairing | 1 |
46 | fel-pump∕fel-probe | 1 |
47 | iii-6 | 1 |
48 | invigorant | 1 |
49 | leucinaemia | 1 |
50 | lna-control | 1 |
51 | midshipmen | 1 |
52 | multi-fiber | 1 |
53 | nano-particle | 1 |
54 | no-ea | 1 |
55 | non-concurrently | 1 |
56 | nonimiquimod | 1 |
57 | o-tolylthiosemicarbazide | 1 |
58 | o2optix | 1 |
59 | outcomes.tcmhs | 1 |
60 | overenmeshment | 1 |
61 | pagoda | 1 |
62 | palladium-catalysis | 1 |
63 | part-ner | 1 |
64 | reimpregnation | 1 |
65 | ridged | 1 |
66 | ritonavir-boosted/nonboosted | 1 |
67 | semi-intermittently | 1 |
68 | solublized | 1 |
69 | synergises | 1 |
70 | tenofovir-df/emtricitabine | 1 |
71 | therapy-primary | 1 |
72 | tinker | 1 |
73 | tma-positive | 1 |
74 | transplantation.compared | 1 |
75 | tryptolines | 1 |
76 | two-visits | 1 |
77 | un-intervened | 1 |
78 | uncontrolled-trials | 1 |
79 | vibrotherapy | 1 |
80 | ziprasidone.compared | 1 |
81 | ≥0.30g/d | 1 |
1 | 1,3-azadienes | 1 |
2 | 2-thienylbbr2·pph3 | 1 |
3 | agpf6 | 1 |
4 | assistant/physical | 1 |
5 | associeted | 1 |
6 | autorefraktokeratometer | 2 |
7 | azathioprine/6-mercaptopurine | 1 |
8 | biflagellate | 2 |
9 | bpi- | 1 |
10 | capsule-based | 5 |
11 | chromoscopic | 2 |
12 | cmc-protocol | 1 |
13 | co-administered | 355 |
14 | co-formulated | 23 |
15 | co-segregating | 4 |
16 | coadministered | 368 |
17 | combined | 29,205 |
18 | cone-erg | 1 |
19 | crimpled | 1 |
20 | cross-pairing | 1 |
21 | diet-based | 4 |
22 | dp-δ24/28cpe | 3 |
23 | eb4k | 3 |
24 | empathizing | 3 |
25 | ergotism | 3 |
26 | fel-pump∕fel-probe | 1 |
27 | formylated | 2 |
28 | hyperpulse | 7 |
29 | iii-6 | 1 |
30 | imidazolyl-3-position | 2 |
31 | information-delivery | 2 |
32 | invigorant | 1 |
33 | leucinaemia | 1 |
34 | lna-control | 1 |
35 | lv-peg | 8 |
36 | medoxomil-induced | 2 |
37 | midshipmen | 1 |
38 | multi-fiber | 1 |
39 | nano-particle | 1 |
40 | neoureterostomy | 3 |
41 | no-ea | 1 |
42 | non-concurrently | 1 |
43 | nonimiquimod | 1 |
44 | not-cured | 2 |
45 | o-tolylthiosemicarbazide | 1 |
46 | o2optix | 1 |
47 | outcomes.tcmhs | 1 |
48 | overenmeshment | 1 |
49 | pa-pals | 4 |
50 | pagoda | 1 |
51 | palladium-catalysis | 1 |
52 | part-ner | 1 |
53 | predosed | 3 |
54 | probiotical | 5 |
55 | puerpera | 2 |
56 | radiotherapy-based | 2 |
57 | refitted | 8 |
58 | reimpregnation | 1 |
59 | ridged | 1 |
60 | ritonavir-boosted/nonboosted | 1 |
61 | semi-intermittently | 1 |
62 | solublized | 1 |
63 | sv-peg | 7 |
64 | synergises | 1 |
65 | tarpana | 4 |
66 | tenofovir-df/emtricitabine | 1 |
67 | therapy-primary | 1 |
68 | thiosemicarbazides | 4 |
69 | tinker | 1 |
70 | tma-positive | 1 |
71 | tocct | 5 |
72 | transplantation.compared | 1 |
73 | trfh | 10 |
74 | tryptolines | 1 |
75 | two-visits | 1 |
76 | ufox | 4 |
77 | un-intervened | 1 |
78 | uncontrolled-trials | 1 |
79 | vibrotherapy | 1 |
80 | ziprasidone.compared | 1 |
81 | ≥0.30g/d | 1 |
1 | bpi- | 1 |
2 | 2-thienylbbr2·pph3 | 1 |
3 | iii-6 | 1 |
4 | agpf6 | 1 |
5 | pagoda | 1 |
6 | no-ea | 1 |
7 | leucinaemia | 1 |
8 | tarpana | 4 |
9 | puerpera | 2 |
10 | chromoscopic | 2 |
11 | ≥0.30g/d | 1 |
12 | medoxomil-induced | 2 |
13 | ridged | 1 |
14 | crimpled | 1 |
15 | un-intervened | 1 |
16 | combined | 29,205 |
17 | ziprasidone.compared | 1 |
18 | transplantation.compared | 1 |
19 | co-administered | 355 |
20 | coadministered | 368 |
21 | not-cured | 2 |
22 | capsule-based | 5 |
23 | diet-based | 4 |
24 | radiotherapy-based | 2 |
25 | predosed | 3 |
26 | co-formulated | 23 |
27 | formylated | 2 |
28 | associeted | 1 |
29 | ritonavir-boosted/nonboosted | 1 |
30 | refitted | 8 |
31 | solublized | 1 |
32 | nonimiquimod | 1 |
33 | fel-pump∕fel-probe | 1 |
34 | o-tolylthiosemicarbazide | 1 |
35 | nano-particle | 1 |
36 | tenofovir-df/emtricitabine | 1 |
37 | azathioprine/6-mercaptopurine | 1 |
38 | dp-δ24/28cpe | 3 |
39 | hyperpulse | 7 |
40 | biflagellate | 2 |
41 | tma-positive | 1 |
42 | lv-peg | 8 |
43 | sv-peg | 7 |
44 | cross-pairing | 1 |
45 | co-segregating | 4 |
46 | empathizing | 3 |
47 | cone-erg | 1 |
48 | trfh | 10 |
49 | eb4k | 3 |
50 | assistant/physical | 1 |
51 | probiotical | 5 |
52 | cmc-protocol | 1 |
53 | lna-control | 1 |
54 | ergotism | 3 |
55 | midshipmen | 1 |
56 | reimpregnation | 1 |
57 | imidazolyl-3-position | 2 |
58 | multi-fiber | 1 |
59 | tinker | 1 |
60 | part-ner | 1 |
61 | autorefraktokeratometer | 2 |
62 | thiosemicarbazides | 4 |
63 | 1,3-azadienes | 1 |
64 | tryptolines | 1 |
65 | synergises | 1 |
66 | outcomes.tcmhs | 1 |
67 | palladium-catalysis | 1 |
68 | uncontrolled-trials | 1 |
69 | pa-pals | 4 |
70 | two-visits | 1 |
71 | tocct | 5 |
72 | invigorant | 1 |
73 | overenmeshment | 1 |
74 | o2optix | 1 |
75 | ufox | 4 |
76 | non-concurrently | 1 |
77 | semi-intermittently | 1 |
78 | neoureterostomy | 3 |
79 | vibrotherapy | 1 |
80 | therapy-primary | 1 |
81 | information-delivery | 2 |